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Abstract
Background: Obstructive sleep apnea (OSA) is a respiratory disease characterized by the collapse of the
extrathoracic airway and has important social implications related to accidents and cardiovascular risk. The main
objective of the present study was to investigate whether the drop in expiratory flow and the volume expired in
0.2 s during the application of negative expiratory pressure (NEP) are associated with the presence and severity of
OSA in a population of professional interstate bus drivers who travel medium and long distances.
Methods/Design: An observational, analytic study will be carried out involving adult male subjects of an interstate
bus company. Those who agree to participate will undergo a detailed patient history, physical examination
involving determination of blood pressure, anthropometric data, circumference measurements (hips, waist and
neck), tonsils and Mallampati index. Moreover, specific questionnaires addressing sleep apnea and excessive
daytime sleepiness will be administered. Data acquisition will be completely anonymous. Following the medical
examination, the participants will perform a spirometry, NEP test and standard overnight polysomnography. The
NEP test is performed through the administration of negative pressure at the mouth during expiration. This is a
practical test performed while awake and requires little cooperation from the subject. In the absence of expiratory
flow limitation, the increase in the pressure gradient between the alveoli and open upper airway caused by NEP
results in an increase in expiratory flow.
Discussion: Despite the abundance of scientific evidence, OSA is still underdiagnosed in the general population. In
addition, diagnostic procedures are expensive, and predictive criteria are still unsatisfactory. Because increased
upper airway collapsibility is one of the main determinants of OSA, the response to the application of NEP could
be a predictor of this disorder. With the enrollment of this study protocol, the expectation is to encounter
predictive NEP values for different degrees of OSA in order to contribute toward an early diagnosis of this
condition and reduce its impact and complications among commercial interstate bus drivers.
Trial registration: Registro Brasileiro de Ensaios Clinicos (local acronym RBEC) [Internet]: Rio de Janeiro (RJ): Instituto de
Informaçao Cientifica e Tecnologica em Saude (Brazil); 2010 - Identifier RBR-7dq5xx. Cross-sectional study on efficacy of
negative expiratory pressure test proposed as screening for obstructive sleep apnea syndrome among commercial
interstate bus drivers; 2011 May 31 [7 pages]. Available from http://www.ensaiosclinicos.gov.br/rg/RBR-7dq5xx/.
* Correspondence: oliveira.lvf@pq.cnpq.br
1Master’s and Doctoral Degree Programs in Rehabilitation Sciences, Nove de
Julho, University, Sao Paulo, Brazil
Full list of author information is available at the end of the article
Hirata et al. BMC Pulmonary Medicine 2011, 11:57
http://www.biomedcentral.com/1471-2466/11/57
© 2011 Hirata et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Sleep disorders are common throughout the world and
have living effects on modern industrialized “24-hour”
societies. The consequences of such disorders include
excessive sleepiness, a negative effect on social and
recreational activities, a decreased physical ability, a
decline in productivity and a high risk of accidents [1].
These conditions, which are associated to acute or
chronic insomnia, chronic sleep restriction, work shifts,
jet lag, narcolepsy and obstructive sleep apnea (OSA),
are a public health concern.
There is a large body of evidence demonstrating that
sleepiness contributes toward industrial and traffic acci-
dents [2]. It has previous been reported that 22% of
accidents are caused by excessive sleepiness and 17-19%
of traffic deaths are the result of sleepiness at the wheel
[3]. The medical and economic costs of traffic accidents
are estimated to be 1 to 3% of the gross domestic pro-
duct of a country (annual cost of approximately 518 bil-
lion dollars). The Instituto de Pesquisa Econômica
Aplicada (IPEA) [Institute of Applied Economic
Research] of the Brazilian Federal Government reports
that the mean cost of traffic accidents in Brazil is US$
5,167,000, among which US$ 1,919.000 are spent on vic-
timless accidents, US$ 2,942,000 are spent on accidents
that result in injuries and US$ 2,476,000 are spent on
accidents involving deaths [4].
OSA is a respiratory disease characterized by the col-
lapse of the upper airways which occurs during sleep in
predisposed subjects. Following chronic obstructive pul-
monary disease and asthma, OSA is the epidemiological
most important and widespread respiratory disease,
affecting 3 to 7% of the male population and 2 to 5% of
the female population between 40 and 65 years of age in
the western world [5]. In Brazil, prevalence even larger
was encountered according to an epidemiological study
carried out in the city of Sao Paulo, where 24.8% males
and 9.6% females were OSA patients [6].
One of the most important social implications of OSA
is the increased risk for driving accidents [7]. Pack et al.
(2002) reported a prevalence of 28% in a population of
professional truck drivers [8]. The main cause of road
accidents among professional drivers is lack of sleep,
disturbance in the sleep/wake cycle (shift workers) and
sleep disorders [9,10].
There is a close relationship between OSA and the
risk of cardiovascular disease [11-13], neuropsychologi-
cal problems [14,15], reduction in quality of life [16,17]
and increase in the use of health resources [18,19],
demonstrating that, when under-diagnosed, OSA can
have serious consequences. Thus, the identification of
new markers for OSA can be of considerable relevance
for clinical practice.
An increase in the upper airway collapsibility is one of
the main determinants of OSA [20,21]. Investigators
have identified anatomical factors [22-24], neuromuscu-
lar control factors [25,26] and liquid and fat deposits
[27] that may lead to increased pharyngeal collapsibility
during sleep.
The negative expiratory pressure (NEP) method was
initially used to assess intrathoracic expiratory flow limita-
tions in patients with chronic obstructive pulmonary dis-
ease [28]. However, NEP test in individuals with OSA was
found to lead to a collapse of the extrathoracic airway,
with a drop in expiratory flow below the preceding expira-
tion, which is common among patients with OSA [29-32].
The NEP test is carried out by administering negative
pressure at the mouth during expiration. This maneuver is
easy to perform and requires minimal patient cooperation.
NEP test is based on the pressure gradient increase
between the alveoli and open upper airway that results in
an increase in expiratory flow. This study will allow the
use of new screening technique to detect upper airway col-
lapsibility, a high risk indicator for OSA in professional
drivers. It’s a daytime, low-cost screening method that
could be included in a preventive strategy aimed at redu-
cing the impact of this condition on accidents and the
development of cardiovascular consequences.
Objectives
The main objective of the study, which will be conducted
on medium and long distance professional interstate bus
drivers, is to investigate whether NEP test induced upper
airway collapse is indicative for the presence and severity
of OSA. Secondary objectives are: 1) identify the preva-
lence of OSA in this population; 2) determine the preva-
lence of metabolic syndrome and cardiovascular disease;
3) determine the correlation of work shift on clinical
findings; and 4) validate a novel questionnaire on sleep
quality proposed by the Italian National Research Coun-
cil Institute of Biomedicine and Molecular Immunology
“A. Monroy” and Centro Medico di Veruno (Italy).
Methods/Design
Study design
An observational, analytical study will be carried out at
the Sleep Laboratory of the Master’s and Doctoral Post-
graduate Program in Rehabilitation Sciences of the Nove
de Julho University (Brazil) (Figure 1). The design, con-
duction and reporting of this study will follow the
norms of the “Standards for the Reporting of Diagnostic
accuracy studies” - STARD statement.
Subjects
Male professional bus drivers of an interstate roadway
firm will be invited to participate in the study. The
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community-based sample includes shift workers: indivi-
duals working regular night shifts (from 10:00 pm to
08:00 am), individuals working regular day shifts (from
08:00 am to 06:00 pm), and subjects working rotating
shifts.
With regard to the inclusion criteria, the sample will
be made up by medium and long distance drivers,
agreeing to participate in the study through a signed
informed consent form. Subjects with acute pulmonary
or heart disease and/or major cranio-facial or upper air-
way abnormalities, drug users and alcoholics will be
excluded from the study.
Protocol
The initial population of professional bus drivers
includes 710 subjects. All will be asked to be part of the
study and all procedures will be clarified. Those who
agree to participate will undergo a detailed patient his-
tory, physical examination involving determination of
blood pressure, anthropometric data, circumference
measurements (hips, waist and neck), tonsils and Mal-
lampati index. Moreover, specific questionnaires addres-
sing sleep apnea and excessive daytime sleepiness will
be administered. Data acquisition will be completely
anonymous. Following the medical examination, the
Figure 1 Design of the study. Abbreviations: ESS - Epworth Sleepiness Scale; CNR - Consiglio Nazionale delle Ricerche; NEP - negative
expiratory pressure.
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participants will perform a spirometry, NEP test and
standard overnight polysomnography.
Physical examination
Weight and height evaluation will be performed through
an electronic balance (model 200/5, Welmy Industria e
Comercio Ltda, Sao Paulo, Brazil) and body mass index
(BMI) will be calculated [33]. For the assessments of
tonsils and Mallampati index, subjects will be in the sit-
ting position and instructed to open the mouth as much
as possible [34,35].
Waist circumference will be measured with the subject
in the upright position, standing at the midpoint
between the costal margin and the iliac crest at the end
of normal expiration. The hip circumference will be
measured with the subject in the same position at the
level of the greater trochanter. Neck circumference will
be measured with the subject in the sitting position at
the edge of the cricoid cartilage.
OSA and excessive daytime sleepiness questionnaires
The Berlin Questionnaire will be administered. This 10-
item questionnaire has recognized efficacy in distin-
guishing subjects at greater risk for OSA in primary
care population [36]. The Epworth Sleepiness Scale [37]
will be used for the assessment of excessive daytime
sleepiness. Moreover, a novel OSA questionnaire
designed by researchers of the Italian National Research
Council - Institute of Biomedicine and Molecular
Immunology “A. Monroy” and Centro Medico di Ver-
uno will be administered.
Spirometry
The spirometry will be carried out during the day, with
the patient seated in a comfortable position. For such,
the KoKo PFT System Version 4.11 (nSpire Health, Inc;
Louisville, CO, USA) will be used following national
guidelines for the execution of lung function tests by
the Brazilian Society of Pneumology [38] and the Eur-
opean Respiratory Society [39]. The subjects will per-
form the test in a comfortable position, with the body
erect and the upper limbs unsupported. All examina-
tions will be carried out by a competent technician
trained in obtaining the necessary cooperation from the
subjects and appropriately operating the equipment in
order to ensure accurate, reproducible results. The
equipment will be calibrated prior to each exam with a
3-L syringe [38].
Negative expiratory pressure - NEP test
The NEP test is performed through the administration
of negative pressure at the mouth during expiration.
This is a practical test performed while awake and
requires little cooperation from the subject. In the
absence of expiratory flow limitation, the increase in the
pressure gradient between the alveoli and open upper
airway caused by NEP results in an increase in expira-
tory flow.
NEP will be generated by a Super Air Amplifier (Exair
model 120021 Cincinnati, Ohio, USA) coupled to a tank
of compressed air via an electrically operated solenoid
valve (Norgren Ltd model 95004; Vimercate, MI, Italy)
automatically activated in early expiration and kept
open for 2 s by software control (Figure 2). A pneumo-
tachograph (Hans Rudolph model 3830; Kansas City,
MO, USA) will be connected to the air amplifier and
the mouthpiece to measure airflow ( V˙ ) with pressure
transducers (PCLA02X5; Sensortechnics GmbH, Puch-
heim, Germany). Mouth pressure will be measured by
pressure transducers (PCLA0050; Sensortechnics
GmbH, Puchheim, Germany). NEP of 10 cm H2O will
be set by occluding the pneumotachograph with a stop-
per and adjusting the flow of compressed air to air
amplifier (Figure 2).
NEP maneuvers will be performed (each after at least
four breaths to normalize the breathing pattern). The
tests will be carried out once with the subjects seated
comfortably and one other in supine position on a cot.
In both positions, care will be taken to maintain the
subjects comfortable with the neck in a neutral position,
as it has been documented that the position of the head
exerts an influence over upper airway collapsibility [40].
All maneuvers will be performed with the subjects
awake and wearing a nose clip. The airflow and the
mouth pressure signals will be low-pass filtered and
sampled at 200 Hz. Both digital signals will be displayed
in real time on the monitor and stored on the computer
for subsequent analysis. Signal analysis and solenoid
Figure 2 Schematic representation of the negative expiratory
pressure apparatus.
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valve control will be performed using software written
in Labview 8.2 (National Instruments) developed by the
Italian National Research Council, Institute of Biomedi-
cine and Molecular Immunology “A. Monroy”.
NEP application during tidal expiration produces an
immediate peak flow followed by a sudden drop of a
variable degree. Upper airway collapsibility is evaluated
by measuring flow limitation as flow drop (Δ V˙ ),
expressed as the percentage of peak flow immediately
after NEP administration. To avoid reflex and voluntary
reactions to the NEP stimulus, the minimal flow will be
identified in the first 200 ms of NEP administration
[41]. Upper airway collapsibility is also evaluated by
measuring V0.2 immediately after NEP administration
(Figure 3). These values are expressed as the percentage
of mean inspiratory volume of the three breaths preced-
ing NEP administration. Measured volumes are accepted
only when differences between inspiration and expira-
tion for each of the three previous breaths are less than
10%. Values of V0.2 and Δ V˙ (%) are calculated as the
mean of four measurements.
Standard overnight polysomnography
Nocturnal polysomnography will be carried out using
the Embla Somnologica Studio - EMBLA A10, version
3.1.2. (Flaga hf. Medical Devices, Iceland) sleep analysis
system. The following signals will be recorded: electro-
encephalogram (F4-M1, C4-M1, O2-M1, and backup
electrodes F3, C3, O1 and M2), electrooculograms (E1-
M2, E2-M2), chin and tibials electromyography, electro-
cardiogram, oxygen saturation, pulse rate, oronasal air-
flow (nasal canula and thermistor), respiratory effort
(thoracic and abdominal Xtrace model straps), snoring,
and body position. The patients will be instructed to
remain relaxed and sleep naturally as at home.
Throughout the night, the subjects will be monitored by
a technician experienced in polysomnography [42]. The
reading will be performed by professionals who were
blinded to the result of the NEP test, following the
guidelines of the American Academy of Sleep Medicine
[43] and criteria of the Brazilian Sleep Society.
Apneas are defined as lack of airflow or a reduction
≥90% in the airflow signal for at least 10 s. Hypopneas
are defined as discernible drop in flow by ≥ 30% of base-
line for a period lasting at least 10 s followed by a SaO2
fall ≥4%. AHI will be calculated as number of (apneas +
hypopneas)/h of total sleep time. Subjects with AHI ≥5
will be classified as OSA [42,43].
Quality control
In order to ensure data quality, the physiotherapists and
physicians in charge of data collection will receive speci-
fic training. Periodic external monitoring will be per-
formed to verify adequate application of methodology in
performing examinations and data collection.
Calculation of sample size and statistical analysis
The calculation of sample size was based on the correla-
tion reported by Insalaco et al. [44] between ΔV˙ (%) and
AHI in patients with OSA (r = 0.37). For a bidirectional
alpha value of 0.05 and 90% power, a minimum number
of 82 subjects will be necessary.
Kolmogorov-Smirnov normality test will first be per-
formed in order to determine the presence or absence of a
normal distribution sample. Descriptive analysis will be
performed, with the data expressed as either mean and
standard deviation or median values and 95% confidence
intervals, when appropriate. One-way analysis of variance
(ANOVA) will be used for comparisons between work
shifts once the samples have a normal distribution. V0.2
and ΔV˙ (%) values will be linearly correlated with the AHI,
for which either Pearson’s or Spearman’s correlation test
will be used, depending on the sample distribution. Either
the non-paired Student’s t-test or Mann-Whitney test will
be used for comparisons between individuals with and
without OSA. Logistic regression for the analysis of con-
tinuous factors with categorical responses will be per-
formed. Receiver operating characteristic (ROC) curves
will be constructed to determine the sensitivity (true posi-
tive rate) versus 100-specificity (false positive rate) at var-
ious levels of the measured Δ V˙ (%) and V0.2 (%) to
identify the cut-off value yielding the largest number of
correctly classified patients. The statistical analysis will be
performed by an experienced statistician using the JMP
commercial program (version 8.0, SAS Institute Inc.) and
SPSS program (version 16.0, Somers NY). A 5% level of
significance and 95% confidence interval will be applied.
Ethical considerations
The present study is in accordance with the Helsinki
Declaration and the Regulatory Guidelines and Norms
Figure 3 Measurements techniques for upper airway
collapsibility evaluated as expiratory volume in 0.2s (V0.2 -
percent of the mean inspiratory volume of the three breaths
preceding NEP application) and as the flow drop (ΔV˙ -
expressed as the percent of the peak flow).
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for Research Involving Human Subjects of the National
Health Board of the Brazilian Health Ministry issued in
October 1996. This study received approval from the
Human Research Ethics Committee of the Nove de
Julho University (Brazil) under process number 329445/
2010. Informed consent will be required to all subjects.
All procedures of the study will be confidential. The
professional drivers diagnosed for OSA will be referred
to the Sleep Medicine service and immediately for-
warded to adequate treatment in order to treat the sleep
respiratory disorder.
Discussion
Despite the abundance of scientific evidence, OSA is still
underdiagnosed in the general population. This is prob-
ably due to multiple causes, such as deficiency of knowl-
edge on the part of physicians and also the limited
access of the patients to diagnosis and treatment of
OSA [45]. In addition, diagnostic procedures are expen-
sive, and predictive criteria are still unsatisfactory. Obe-
sity parameters are important predictors, although not
all OSA patients are obese and not all obese subjects
have OSA. The identification of new markers of OSA
would be useful.
The aim of the present protocol study is to determine
whether the NEP test could be used as a screening tool
for OSA and the prevalence of this condition among a
population of professional interstate bus drivers. Because
increased upper airway collapsibility is one of
the main determinants of OSA [21], the response to
the application of NEP could be a predictor of this
disorder.
With the enrollment of this study protocol, the expec-
tation is to encounter predictive NEP values for different
degrees of OSA. It’s a daytime, low-cost screening
method that could be included in a preventive strategy
in order to contribute toward an early diagnosis of this
condition and reduce its impact and complications
among professional interstate bus drivers.
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